Zimmer Biomet Holdings, Inc. (ZBH)
USD 105.86
(-2.04%)
USD 105.86
(-2.04%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 4.86 Billion USD | -5.52% |
| 2022 | 5.15 Billion USD | -5.88% |
| 2021 | 5.47 Billion USD | -28.22% |
| 2020 | 7.62 Billion USD | 13.47% |
| 2019 | 6.72 Billion USD | -20.35% |
| 2018 | 8.43 Billion USD | -5.37% |
| 2017 | 8.91 Billion USD | -16.42% |
| 2016 | 10.66 Billion USD | -7.67% |
| 2015 | 11.55 Billion USD | 710.68% |
| 2014 | 1.42 Billion USD | -14.76% |
| 2013 | 1.67 Billion USD | -2.82% |
| 2012 | 1.72 Billion USD | 9.19% |
| 2011 | 1.57 Billion USD | 37.99% |
| 2010 | 1.14 Billion USD | 1.29% |
| 2009 | 1.12 Billion USD | 145.08% |
| 2008 | 460.1 Million USD | 341.13% |
| 2007 | 104.3 Million USD | 4.72% |
| 2006 | 99.6 Million USD | 22.06% |
| 2005 | 81.6 Million USD | -86.92% |
| 2004 | 624 Million USD | -38.08% |
| 2003 | 1 Billion USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 213.9 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 4.82 Billion USD | -0.86% |
| 2024 Q3 | 4.85 Billion USD | 19.74% |
| 2024 Q2 | 3.95 Billion USD | -18.02% |
| 2023 FY | 4.86 Billion USD | -5.52% |
| 2023 Q1 | 5.2 Billion USD | 1.02% |
| 2023 Q2 | 5.18 Billion USD | -0.3% |
| 2023 Q3 | 5.12 Billion USD | -1.19% |
| 2023 Q4 | 4.86 Billion USD | -5.06% |
| 2022 Q4 | 5.15 Billion USD | -1.58% |
| 2022 Q1 | 5.28 Billion USD | -3.43% |
| 2022 Q2 | 5.29 Billion USD | 0.25% |
| 2022 Q3 | 5.23 Billion USD | -1.22% |
| 2022 FY | 5.15 Billion USD | -5.88% |
| 2021 Q3 | 6.46 Billion USD | -4.9% |
| 2021 Q1 | 7.53 Billion USD | -1.15% |
| 2021 Q2 | 6.8 Billion USD | -9.79% |
| 2021 FY | 5.47 Billion USD | -28.22% |
| 2021 Q4 | 5.47 Billion USD | -15.36% |
| 2020 Q4 | 7.62 Billion USD | -2.68% |
| 2020 Q1 | 7.71 Billion USD | 14.84% |
| 2020 FY | 7.62 Billion USD | 13.47% |
| 2020 Q2 | 7.75 Billion USD | 0.53% |
| 2020 Q3 | 7.83 Billion USD | 0.99% |
| 2019 FY | 6.72 Billion USD | -20.35% |
| 2019 Q2 | 6.71 Billion USD | -19.15% |
| 2019 Q3 | 6.33 Billion USD | -5.68% |
| 2019 Q4 | 6.72 Billion USD | 6.06% |
| 2019 Q1 | 8.31 Billion USD | -1.05% |
| 2018 Q3 | 8.59 Billion USD | -8.48% |
| 2018 Q4 | 8.39 Billion USD | -2.31% |
| 2018 FY | 8.43 Billion USD | -5.37% |
| 2018 Q2 | 9.39 Billion USD | -0.98% |
| 2018 Q1 | 9.48 Billion USD | 6.39% |
| 2017 Q3 | 9.19 Billion USD | -1.65% |
| 2017 Q2 | 9.35 Billion USD | -11.23% |
| 2017 Q1 | 10.53 Billion USD | -1.24% |
| 2017 FY | 8.91 Billion USD | -16.42% |
| 2017 Q4 | 8.91 Billion USD | -3.07% |
| 2016 Q3 | 11 Billion USD | 4.49% |
| 2016 Q1 | 11.11 Billion USD | -3.57% |
| 2016 Q4 | 10.66 Billion USD | -3.06% |
| 2016 FY | 10.66 Billion USD | -7.67% |
| 2016 Q2 | 10.53 Billion USD | -5.25% |
| 2015 Q3 | 11.68 Billion USD | -0.51% |
| 2015 Q2 | 11.74 Billion USD | 29.67% |
| 2015 Q1 | 9.06 Billion USD | 546.54% |
| 2015 FY | 11.55 Billion USD | 710.68% |
| 2015 Q4 | 11.52 Billion USD | -1.37% |
| 2014 Q1 | 1.68 Billion USD | 0.47% |
| 2014 Q4 | 1.4 Billion USD | -1.75% |
| 2014 Q2 | 1.68 Billion USD | 0.43% |
| 2014 FY | 1.42 Billion USD | -14.76% |
| 2014 Q3 | 1.42 Billion USD | -15.47% |
| 2013 Q1 | 1.7 Billion USD | 0.94% |
| 2013 FY | 1.67 Billion USD | -2.82% |
| 2013 Q4 | 1.67 Billion USD | -0.81% |
| 2013 Q3 | 1.68 Billion USD | -0.12% |
| 2013 Q2 | 1.68 Billion USD | -0.86% |
| 2012 Q2 | 1.72 Billion USD | 9.77% |
| 2012 Q1 | 1.57 Billion USD | -0.2% |
| 2012 FY | 1.72 Billion USD | 9.19% |
| 2012 Q4 | 1.68 Billion USD | -2.72% |
| 2012 Q3 | 1.73 Billion USD | 0.44% |
| 2011 Q2 | 1.14 Billion USD | 0.62% |
| 2011 Q3 | 1.54 Billion USD | 34.53% |
| 2011 Q4 | 1.57 Billion USD | 2.11% |
| 2011 FY | 1.57 Billion USD | 37.99% |
| 2011 Q1 | 1.14 Billion USD | -0.17% |
| 2010 Q4 | 1.14 Billion USD | 0.31% |
| 2010 Q2 | 1.13 Billion USD | 0.32% |
| 2010 FY | 1.14 Billion USD | 1.29% |
| 2010 Q1 | 1.12 Billion USD | -0.05% |
| 2010 Q3 | 1.13 Billion USD | 0.71% |
| 2009 FY | 1.12 Billion USD | 145.08% |
| 2009 Q4 | 1.12 Billion USD | 87.87% |
| 2009 Q3 | 600.2 Million USD | -8.16% |
| 2009 Q2 | 653.5 Million USD | -1.04% |
| 2009 Q1 | 660.4 Million USD | 43.53% |
| 2008 FY | 460.1 Million USD | 341.13% |
| 2008 Q1 | 116.9 Million USD | 12.08% |
| 2008 Q2 | 329.3 Million USD | 181.69% |
| 2008 Q3 | 331.1 Million USD | 0.55% |
| 2008 Q4 | 460.1 Million USD | 38.96% |
| 2007 Q1 | 100 Million USD | 0.4% |
| 2007 Q4 | 104.3 Million USD | 1.07% |
| 2007 Q3 | 103.2 Million USD | 8.4% |
| 2007 Q2 | 95.2 Million USD | -4.8% |
| 2007 FY | 104.3 Million USD | 4.72% |
| 2006 FY | 99.6 Million USD | 22.06% |
| 2006 Q1 | 81.5 Million USD | -0.12% |
| 2006 Q2 | 82.6 Million USD | 1.35% |
| 2006 Q3 | 100.9 Million USD | 22.15% |
| 2006 Q4 | 99.6 Million USD | -1.29% |
| 2005 Q1 | 426.3 Million USD | -31.68% |
| 2005 FY | 81.6 Million USD | -86.92% |
| 2005 Q2 | 268.1 Million USD | -37.11% |
| 2005 Q3 | 85.8 Million USD | -68.0% |
| 2005 Q4 | 81.6 Million USD | -4.9% |
| 2004 Q1 | 959.7 Million USD | -4.77% |
| 2004 Q4 | 624 Million USD | -6.57% |
| 2004 Q3 | 667.9 Million USD | -23.13% |
| 2004 Q2 | 868.9 Million USD | -9.46% |
| 2004 FY | 624 Million USD | -38.08% |
| 2003 FY | 1 Billion USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | 1 Billion USD | 0.0% |
| 2002 Q3 | 98.9 Million USD | -39.25% |
| 2002 Q1 | 192.2 Million USD | -10.14% |
| 2002 Q2 | 162.8 Million USD | -15.3% |
| 2002 FY | - USD | -100.0% |
| 2002 Q4 | - USD | -100.0% |
| 2001 Q3 | 258.3 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | 213.9 Million USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | 213.9 Million USD | -17.19% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Abbott Laboratories | 13.59 Billion USD | 64.204% |
| Allurion Technologies Inc. | 2.3 Million USD | -210997.138% |
| Artivion, Inc. | 305.53 Million USD | -1493.259% |
| Avanos Medical, Inc. | 159.4 Million USD | -2953.89% |
| Butterfly Network, Inc. | 22.83 Million USD | -21217.714% |
| Butterfly Network, Inc. | 22.83 Million USD | -21217.714% |
| Bio-Rad Laboratories, Inc. | 1.18 Billion USD | -309.256% |
| Boston Scientific Corporation | 8.96 Billion USD | 45.677% |
| Perspective Therapeutics, Inc. | - USD | -Infinity% |
| CONMED Corporation | 971.48 Million USD | -401.079% |
| Edwards Lifesciences Corporation | 670 Million USD | -626.552% |
| Paragon 28, Inc. | 109.79 Million USD | -4333.465% |
| Glaukos Corporation | 383.73 Million USD | -1168.548% |
| Globus Medical, Inc. | 417.4 Million USD | -1066.243% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -19492.288% |
| Integer Holdings Corporation | 959.92 Million USD | -407.113% |
| Medtronic plc | 23.87 Billion USD | 79.613% |
| Nevro Corp. | 211.47 Million USD | -2201.923% |
| Owlet, Inc. | 22 Thousand USD | -22126718.182% |
| Penumbra, Inc. | 220.9 Million USD | -2103.577% |
| Vicarious Surgical Inc. | 13.78 Million USD | -35213.021% |
| Smith & Nephew plc | 2.17 Billion USD | -123.811% |
| Sonendo, Inc. | 14.03 Million USD | -34584.004% |
| STERIS plc | 3.12 Billion USD | -56.014% |
| Stryker Corporation | 10.9 Billion USD | 55.344% |
| Vapotherm, Inc. | 109.97 Million USD | -4326.249% |